Literature DB >> 22332135

Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis.

Jodi Goodwin1, Naomi Spitale, Asma Yaghi, Myrna Dolovich, Parameswaran Nair.   

Abstract

The present case series describes four patients with asthma, airway hyperresponsiveness and neutrophilic bronchitis who harboured abnormal cystic fibrosis transmembrance conductance regulator (CFTR) gene mutations. It serves both to alert clinicians to consider CFTR-related disease in both young and elderly patients with persistent neutrophilic bronchitis, and to highlight the potential utility of future genetic testing for CFTR abnormalities in patients with asthma and recurrent bronchitis or pansinusitis, and the role of nebulized hypertonic saline as a therapeutic option in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332135      PMCID: PMC3299051          DOI: 10.1155/2012/546702

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  21 in total

1.  CFTR and asthma in the French EGEA study.

Authors:  R de Cid; J C Chomel; C Lazaro; J Sunyer; M Baudis; T Casals; N Le Moual; A Kitzis; J Feingold; J Anto; X Estivill; F Kauffmann
Journal:  Eur J Hum Genet       Date:  2001-01       Impact factor: 4.246

Review 2.  Inhaled hyperosmolar agents for bronchiectasis.

Authors:  P Wills; M Greenstone
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.

Authors:  Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

4.  Measuring bronchitis in airway diseases: clinical implementation and application: Airway hyperresponsiveness in asthma: its measurement and clinical significance.

Authors:  Parameswaran Nair; Frederick E Hargreave
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

5.  Asthma and pulmonary function abnormalities in heterozygotes for cystic fibrosis transmembrane regulator gene mutations.

Authors:  Konstantinos Douros; Ioanna Loukou; Stavros Doudounakis; Maria Tzetis; Kostas N Priftis; Emmanuel Kanavakis
Journal:  Int J Clin Exp Med       Date:  2008-10-27

Review 6.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

7.  Prospective assessment of protracted bacterial bronchitis: airway inflammation and innate immune activation.

Authors:  Julie M Marchant; Peter G Gibson; Terry V Grissell; Naomi L Timmins; I Brent Masters; Anne B Chang
Journal:  Pediatr Pulmonol       Date:  2008-11

8.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

9.  DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma.

Authors:  M Dahl; A Tybjaerg-Hansen; P Lange; B G Nordestgaard
Journal:  Lancet       Date:  1998-06-27       Impact factor: 79.321

10.  Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis.

Authors:  S A Schroeder; D M Gaughan; M Swift
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

View more
  7 in total

1.  The role of CFTR mutations in asthma.

Authors:  Andrew Sandford
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

Review 2.  The therapeutic potential of CFTR modulators for COPD and other airway diseases.

Authors:  George M Solomon; Lianwu Fu; Steven M Rowe; James F Collawn
Journal:  Curr Opin Pharmacol       Date:  2017-11-10       Impact factor: 5.547

Review 3.  Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.

Authors:  S Vamsee Raju; George M Solomon; Mark T Dransfield; Steven M Rowe
Journal:  Clin Chest Med       Date:  2015-12-24       Impact factor: 2.878

4.  CFTR heterozygosity in severe asthma with recurrent airway infections: a retrospective review.

Authors:  Eldar Priel; Adil Adatia; Melanie Kjarsgaard; Parameswaran Nair
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-06       Impact factor: 3.373

Review 5.  Role of CFTR in epithelial physiology.

Authors:  Vinciane Saint-Criq; Michael A Gray
Journal:  Cell Mol Life Sci       Date:  2016-10-06       Impact factor: 9.261

Review 6.  Epithelial Sodium and Chloride Channels and Asthma.

Authors:  Wen Wang; Hong-Long Ji
Journal:  Chin Med J (Engl)       Date:  2015-08-20       Impact factor: 2.628

Review 7.  CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.

Authors:  Sheylan D Patel; Taylor R Bono; Steven M Rowe; George M Solomon
Journal:  Eur Respir Rev       Date:  2020-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.